South Korea-based Daewoong Pharmaceutical has entered a research collaboration with Sygnature Discovery to expand its global open innovation for novel drug development.
Daewoong Pharmaceutical enters research collaboration to discover a novel small molecule to target autoimmune diseases using fragment-based drug discovery and virtual high throughput screening
Sygnature Discovery will provide its proprietary Fragment-Based Drug Discovery (FBDD) and virtual high throughput screening (vHTS) to accelerate Daewoong’s novel drug discovery for autoimmune diseases.
In addition, Daewoong will receive support in protein science and crystallography to validate and secure mechanism of action. Through this collaboration,
Daewoong Pharmaceutical expects to broaden its drug discovery scope to the field of protein-protein interaction (PPI) as a part of next-generation drug discovery strategy.
Also Read : Autoimmune Disease management with right food
(With inputs from The OnLook News Research Bureau)
If you like this article and if you feel it will be helpful for others to understand on the subject, please share it. You can also follow us on Twitter, Facebook & Linkedin
![](https://theonlook.com/wp-content/uploads/2023/10/For-wordpress.jpg")
